Sphera Funds Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,002,783
| Closed | -$5.86M | – | 99 |
|
|
2022
Q4 | $5.86M | Buy |
1,002,783
+50,000
| +5% | +$263K | 1.26% | 27 |
|
|
2022
Q3 | $6.38M | Buy |
952,783
+273,383
| +40% | +$1.66M | 0.89% | 36 |
|
|
2022
Q2 | $2.86M | Buy |
+679,400
| New | +$2.69M | 0.31% | 34 |
|
|
2021
Q1 | – | Sell |
-384,039
| Closed | -$4.85M | – | 210 |
|
|
2020
Q4 | $4.85M | Buy |
384,039
+74,039
| +24% | +$844K | 0.43% | 67 |
|
|
2020
Q3 | $3.04M | Sell |
310,000
-390,710
| -56% | -$3.85M | 0.3% | 73 |
|
|
2020
Q2 | $6.97M | Sell |
700,710
-312,329
| -31% | -$3M | 0.66% | 41 |
|
|
2020
Q1 | $8.96M | Buy |
1,013,039
+873,039
| +624% | +$8.61M | 1.12% | 20 |
|
|
2019
Q4 | $1.29M | Hold |
140,000
| – | – | 0.11% | 80 |
|
|
2019
Q3 | $823K | Buy |
+140,000
| New | +$1.49M | 0.13% | 72 |
|
|
2016
Q1 | – | Sell |
-180,000
| Closed | -$3.42M | – | 128 |
|
|
2015
Q4 | $3.42M | Sell |
180,000
-20,000
| -10% | -$435K | 0.5% | 44 |
|
|
2015
Q3 | $3.75M | Buy |
200,000
+184,142
| +1,161% | +$3.13M | 0.48% | 43 |
|
|
2015
Q2 | $236K | Sell |
15,858
-359,142
| -96% | -$5.47M | 0.02% | 128 |
|
|
2015
Q1 | $5.68M | Buy |
375,000
+225,000
| +150% | +$3.14M | 0.59% | 35 |
|
|
2014
Q4 | $2M | Buy |
150,000
+127,300
| +561% | +$1.64M | 0.34% | 89 |
|
|
2014
Q3 | $286K | Buy |
+22,700
| New | +$220K | 0.04% | 121 |
|
Sphera Funds Management's CNCE Position: Q1 2023 in Review
Sphera Funds Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,002,783 shares — an estimated $5.86M sold.
Sphera Funds Management first reported a position in CNCE in Q3 2014 and held it in 15 quarters. The position peaked at $8.96M in Q1 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Sphera Funds Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Sphera Funds Management sold 1,002,783 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $5.86M.
- Sphera Funds Management first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 15 quarters.
- Sphera Funds Management's Concert Pharmaceuticals, Inc. position peaked at $8.96M in Q1 2020.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Sphera Funds Management's 13F filing for Q1 2023, filed 15 May 2023.